Hsd17b1) Inhibitor for Endometriosis

Total Page:16

File Type:pdf, Size:1020Kb

Hsd17b1) Inhibitor for Endometriosis DEVELOPMENT OF HYDROXYSTEROID (17-BETA) DEHYDROGENASE TYPE 1 (HSD17B1) INHIBITOR FOR ENDOMETRIOSIS Niina Saarinen1,2, Tero Linnanen1, Jasmin Tiala1, Camilla Stjernschantz1, Leena Hirvelä1, Taija Heinosalo2, Bert Delvoux3, Andrea Romano3, Gabriele Möller4, Jerzy Adamski4, Matti Poutanen2, Pasi Koskimies1 1Forendo Pharma Ltd, Finland; 2Institute of Biomedicine, Research Centre for Integrative Physiology and Pharmacology, University of Turku, Finland; 3Department of Obstetrics and Gynaecology; GROW, School for Oncology and Developmental Biology; Maastricht University Medical Centre, The Netherlands; 4Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, Germany BACKGROUND OBJECTIVE Local activation of estrogens in endometriosis tissue The main objective of the present work was to assess is considered important for growth of the lesions. the preclinical efficacy of the novel HSD17B1 inhibitor, Hydroxysteroid (17-beta) dehydrogenase type 1 FOR-6219 (HSD17B1) is expressed in endometriosis tissue and converts the biologically low-active estrogen, estrone (E1), to the highly active estradiol (E2), while hydroxysteroid (17-beta) dehydrogenase type 2 (HSD17B2), catalyzes the opposite reaction. In contrast to eutopic endometrium, in endometriotic lesions the HSD17B1/HSD17B2 expression ratio is increased and E2 levels are higher than those of E1 throughout the menstrual cycle. Thus, inhibition of HSD17B1 is considered as a feasible strategy for lowering local E2 production in endometriosis. MAIN RESULTS FOR-6219 inhibits human HSD17B1 Ø FOR-6219 is a potent and FOR-6219 does not trigger estrogenic fully selective inhibitor of response in immature rat uterine human HSD17B1 over growth assay HSD17B2 Ø FOR-6219 does not bind to estrogen receptor α or β, and exhibits no estrogen-like response in immature rat uterotrophic assay Ø FOR-6219 inhibits HSD17B1 in cynomolgus monkey, dog and rabbit i.e. in species FOR-6219 does not inhibit other HSD17Bs allowing toxicological and FOR-6219 inhibits selectively HSD17B1 HSD17B2 HSD17B3 HSD17B4 HSD17B7 HSD17B14 HSD17B5 pharmacodynamic studies orthologs present in other species AKR1C3 Cynomolgus Dog Rabbit Rat/ IC50 (nM) >10000 >5000 >5000 >5000 >5000 920 monkey Mouse Inhibition % Ø FOR-6219 inhibits E2 at 1µM 0 0 0 0 14 61 formation from E1 in IC50 (nM) 290 48 148 >10000 endometriosis tissue ex vivo CONCLUSIONS FOR-6219 inhibits E2 formation in ü FOR-6219 is a novel and potent HSD17B1 endometriosis inhibitor and a suitable candidate for drug development for endometriosis ü FOR-6219 is highly specific for human HSD17B1 and selectively inhibits the orthologs present in other species ü Non-clinical regulatory studies needed for the first in-human trials have been completed.
Recommended publications
  • Association Between CYP17A1, CYP19A1, and HSD17B1 Gene Polymorphisms in Hormone Synthesis Pathway with Ovarian Cancer Risk
    Association between CYP17A1, CYP19A1, and HSD17B1 Gene Polymorphisms in Hormone Synthesis pathway with Ovarian Cancer Risk Gowtham Kumar G1, Andrea Francis1, Solomon Paul1, Chirag Molia1, Manickavasagam M1, Usha Rani1, Ramya R1, and Nalini Ganesan1 1Sri Ramachandra Institute of Higher Education and Research August 27, 2020 Abstract Objective: To investigate the polymorphisms of genes in the steroidogenesis pathway to understand the etiological mechanisms to OC risk in the South Indian population Design: Case-Control Study Setting and Sample: Ovarian cancer cases (200) and healthy individuals (200) from the South Indian population. Methods: All the cases and controls were genotyped for SNPs by using allelic discrimination assay. Main outcome measures: Genetic distribution of SNPs of Steroidogenesis pathway genes in the South Indian population. Results: The observed results for rs743752, the homozygous CC genotype revealed significant association (OR; 1.68; 95%CI, 1.25-2.26; p =<0.05) and the dominant model, recessive model and additive model showed a significant association with an OR of 1.62; 95%CI, 1.09 { 2.42; p = 0.015, OR of 0.29, 95%CI, 0.14 { 0.60; p = <0.001 and OR of 1.68, 95%CI, 1.25 { 2.26); p = <0.001 respectively in cases and controls for OC risk. In rs10046, the heterozygous CT genotype (OR; 1.61; 95%CI 1.06 { 2.43; p = 0.023), the dominant (OR; 1.65; 95%CI, 1.11 { 2.45; p = 0.012) and the additive (OR; 1.46; 95%CI, 1.07 - 1.98; p = 0.015) models were found to be statistically significant.
    [Show full text]
  • Intratumoral Estrogen Disposition in Breast Cancer
    Published OnlineFirst March 9, 2010; DOI: 10.1158/1078-0432.CCR-09-2481 Published Online First on March 9, 2010 as 10.1158/1078-0432.CCR-09-2481 Clinical Human Cancer Biology Cancer Research Intratumoral Estrogen Disposition in Breast Cancer Ben P. Haynes1, Anne Hege Straume3,4, Jürgen Geisler6, Roger A'Hern7, Hildegunn Helle5, Ian E. Smith2, Per E. Lønning3,5, and Mitch Dowsett1 Abstract Purpose: The concentration of estradiol (E2) in breast tumors is significantly higher than that in plas- ma, particularly in postmenopausal women. The contribution of local E2 synthesis versus uptake of E2 from the circulation is controversial. Our aim was to identify possible determinants of intratumoral E2 levels in breast cancer patients. Experimental Design: The expression of genes involved in estrogen synthesis, metabolism, and sig- naling was measured in 34 matched samples of breast tumor and normal breast tissue, and their corre- lation with estrogen concentrations assessed. Results: ESR1 (9.1-fold; P < 0.001) and HSD17B7 (3.5-fold; P < 0.001) were upregulated in ER+ tumors compared with normal tissues, whereas STS (0.34-fold; P < 0.001) and HSD17B5 (0.23-fold; P < 0.001) were downregulated. Intratumoral E2 levels showed a strong positive correlation with ESR1 expression in all patients (Spearman r = 0.55, P < 0.001) and among the subgroups of postmenopausal (r = 0.76, P < 0.001; n = 23) and postmenopausal ER+ patients (r = 0.59, P = 0.013; n = 17). HSD17B7 expression showed a significant positive correlation (r =0.59,P < 0.001) whereas HSD17B2 (r = −0.46, P = 0.0057) and HSD17B12 (r = −0.45, P = 0.0076) showed significant negative correlations with intratumoral E2 in all patients.
    [Show full text]
  • Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’S Biological Network Based on Systematic Pharmacology
    ORIGINAL RESEARCH published: 25 June 2021 doi: 10.3389/fphar.2021.601846 Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury’s Biological Network Based on Systematic Pharmacology Kailin Yang 1†, Liuting Zeng 1†, Anqi Ge 2†, Yi Chen 1†, Shanshan Wang 1†, Xiaofei Zhu 1,3† and Jinwen Ge 1,4* Edited by: 1 Takashi Sato, Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of 2 Tokyo University of Pharmacy and Life Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, China, Galactophore Department, The First 3 Sciences, Japan Hospital of Hunan University of Chinese Medicine, Changsha, China, School of Graduate, Central South University, Changsha, China, 4Shaoyang University, Shaoyang, China Reviewed by: Hui Zhao, Capital Medical University, China Background: Clinical research found that Hedysarum Multijugum Maxim.-Chuanxiong Maria Luisa Del Moral, fi University of Jaén, Spain Rhizoma Compound (HCC) has de nite curative effect on cerebral ischemic diseases, *Correspondence: such as ischemic stroke and cerebral ischemia-reperfusion injury (CIR). However, its Jinwen Ge mechanism for treating cerebral ischemia is still not fully explained. [email protected] †These authors share first authorship Methods: The traditional Chinese medicine related database were utilized to obtain the components of HCC. The Pharmmapper were used to predict HCC’s potential targets. Specialty section: The CIR genes were obtained from Genecards and OMIM and the protein-protein This article was submitted to interaction (PPI) data of HCC’s targets and IS genes were obtained from String Ethnopharmacology, a section of the journal database.
    [Show full text]
  • Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
    Published OnlineFirst September 18, 2018; DOI: 10.1158/1078-0432.CCR-18-2392 Translational Cancer Mechanisms and Therapy Clinical Cancer Research Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression Xiaomei Gao1,2, Charles Dai3, Shengsong Huang4, Jingjie Tang1,2, Guoyuan Chen1, Jianneng Li3, Ziqi Zhu3, Xuyou Zhu5, Shuirong Zhou1,2, Yuanyuan Gao1,2, Zemin Hou1,2, Zijun Fang1,2, Chengdang Xu4, Jianyang Wang1,2, Denglong Wu4, Nima Sharifi3,6,7, and Zhenfei Li1,2 Abstract Purpose: Steroidogenic enzymes are essential for prostate (DHT) to each of their upstream precursors. HSD17B2 over- cancer development. Enzymes inactivating potent androgens expression suppressed androgen-induced cell proliferation were not investigated thoroughly, which leads to limited inter- and xenograft growth. Multiple mechanisms were involved ference strategies for prostate cancer therapy. Here we charac- in HSD17B2 functional silencing including DNA methylation terizedtheclinical relevance,significance, andregulation mech- and mRNA alternative splicing. DNA methylation decreased anism of enzyme HSD17B2 in prostate cancer development. the HSD17B2 mRNA level. Two new catalytic-deficient iso- Experimental Design: HSD17B2 expression was detected forms, generated by alternative splicing, bound to wild-type with patient specimens and prostate cancer cell lines. Function 17bHSD2 and promoted its degradation. Splicing factors of HSD17B2 in steroidogenesis, androgen receptor (AR) sig- SRSF1 and SRSF5 participated in the generation of new naling, and tumor growth was investigated with prostate isoforms. cancer cell lines and a xenograft model. DNA methylation Conclusions: Our findings provide evidence of the clinical and mRNA alternative splicing were investigated to unveil the relevance, significance, and regulation of HSD17B2 in prostate mechanisms of HSD17B2 regulation.
    [Show full text]
  • Treating Endometriosis
    ADVERTISEMENT FEATURE Forendo Pharma forendo.com Treating endometriosis By using a tissue-specific hormone inhibitor to rebalance local estrogen metabolism, Forendo Pharma could provide long-term treatment to millions of women suffering from endometriosis. With its expertise in tissue-specific hormone O OH therapies, the Finnish company Forendo Pharma HSD17B1 is tackling endometriosis, a condition that affects 10% of women of childbearing age. “Endometriosis is a difficult condition to treat, mainly because the estrogen-deficiency symptoms generated by HSD17B2 the currently used drugs prevent long-term use. HO HO profile Unlike these therapies, our strategy uses novel Estrone (E1) Estradiol (E2) 17-β-hydroxysteroid dehydrogenase (HSD17B) * Low activity * Highly active inhibitors which act locally, without impacting the Figure 1: Forendo’s FOR-6219. The basic concept behind the HSD17B1 inhibitor involves blockage of the systemic estrogen level,” said company CEO Risto conversion of estrone to estradiol. Lammintausta. The company was founded in 2013 by Finnish estrogen action, by converting non-active estrone cannot be controlled with hormonal therapies or drug development pioneers to exploit the find- into active estradiol within endometrial cells. When even surgery. “Whilst more efficient tools for diagno- ings of leading endocrinology researchers Matti this pathway is blocked, the build-up of high levels sis also need to be developed in order to provide an Poutanen and Antti Perheentupa, from the University of the estrogenic hormone estradiol is prevented, opportunity to treat women at an earlier stage and of Turku and Turku University Hospital, Finland. Led which will limit the ability of endometrial cells to form prevent these problems, HSD17B1 inhibitors offer a by Lammintausta, who has over 30 years of experi- endometriotic lesions.
    [Show full text]
  • WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/190970 Al 18 October 2018 (18.10.2018) W !P O PCT (51) International Patent Classification: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, CI2Q 1/32 (2006.01) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, PCT/US2018/021 109 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (22) International Filing Date: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 06 March 2018 (06.03.2018) KM, ML, MR, NE, SN, TD, TG). (25) Filing Language: English Declarations under Rule 4.17: (26) Publication Langi English — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1 7(H)) (30) Priority Data: — as to the applicant's entitlement to claim the priority of the 62/484,141 11 April 2017 ( 11.04.2017) US earlier application (Rule 4.17(Hi)) (71) Applicant: REGENERON PHARMACEUTICALS, Published: INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, — with international search report (Art. 21(3)) New York 10591-6707 (US). — with sequence listing part of description (Rule 5.2(a)) (72) Inventors: STEVIS, Panayiotis; 777 Old Saw Mill Riv er Road, Tarrytown, New York 10591-6707 (US).
    [Show full text]
  • Dottorato Di Ricerca the Effect of Finasteride
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UniCA Eprints Università degli Studi di Cagliari DOTTORATO DI RICERCA Scuola di Dottorato in Neuroscienze e Scienze Morfologiche Corso di Dottorato in Neuroscienze Ciclo XXIII THE EFFECT OF FINASTERIDE IN TOURETTE SYNDROME: RESULTS OF A CLINICAL TRIAL Settore scientifico disciplinari di afferenza BIO/14 Presentata da: Silvia Paba Coordinatore Dottorato Prof.ssa Alessandra Concas Tutor Dott.ssa Paola Devoto Esame finale anno accademico 2009 - 2010 1. INTRODUCTION 1 1.1 General characteristics of steroid 5α-reductase 2 1.2 S5αR inhibitors 15 1.3 S5αR inhibitors as putative therapeutic agents for some neuropsychiatric disorders. 23 2. AIMS OF THE STUDY 37 3. METHODS 38 3.1 Subjects 38 3.2 Procedures 39 3.3 Data analysis 40 4. RESULTS 41 4.1 Description of sample 41 4.2 Dosing, range and compliance 41 4.3 Effects of finasteride on TS and tic severity 44 4.4 Effects of finasteride on obsessive compulsive symptoms 46 4.5 Adverse effects 47 5. DISCUSSION 48 6. CONCLUSION 52 REFERENCES 54 1. INTRODUCTION The enzyme steroid 5α reductase (S5αR) catalyzes the conversion of Δ4-3-ketosteroid precursors - such as testosterone, progesterone and androstenedione - into their 5α- reduced metabolites. Although the current nomenclature assigns five enzymes to the S5αR family, only the types 1 and 2 appear to play an important role in steroidogenesis, mediating an overlapping set of reactions, albeit with distinct chemical characteristics and anatomical distribution. The discovery that the 5α-reduced metabolite of testosterone, 5α-dihydrotestosterone (DHT), is the most potent androgen and stimulates prostatic growth led to the development of S5αR inhibitors with high efficacy and tolerability.
    [Show full text]
  • A Challenge for Medicinal Chemistry by the 17Β-Hydroxysteroid Dehydro
    Send Orders of Reprints at [email protected] 1164 Current Topics in Medicinal Chemistry, 2013, 13, 1164-1171 A Challenge for Medicinal Chemistry by the 17-hydroxysteroid Dehydro- genase Superfamily: An Integrated Biological Function and Inhibition Study S.-X. Lina,b, D. Poiriera and J. Adamskic,d.e aLaboratory of Molecular Endocrinology and Oncology, Centre Hospitalier Universitaire (CHU) de Quebec Research Center (CHUL) and Laval University, Québec City, Québec, G1V4G2, Canada; bWHO Collaborating Center for Re- search in Human Reproductive Health, Shanghai, 200031, China; cHelmholtz Zentrum München, Institute of Experi- mental Genetics, Genome Analysis Center, 85764 Neuherberg, Germany; dLehrstuhl für Experimentelle Genetik, Tech- nische Universität München, 85350 Freising-Weihenstephan, Germany; eGerman Center for Diabetes Research (DZD), 85764 Neuherberg, Germany Abstract: Members of the 17-hydroxysteroid dehydrogenase (17-HSD) superfamily perform distinct multiple catalyses by the same enzyme, apparently contradictory to the long-held beliefs regarding the high specificity of enzymes. Surpris- ingly, these multi-catalyses can combine synergistically in vitro and in vivo and their dysfunction may result in the stimu- lation of breast or prostate cancer. 17-HSD1 possesses high estrogen activation activity, while its androgen inactivation is significant for decreasing the week concentration of dihydrotestosterone (DHT) in breast cancer cells, an important fac- tor for cell proliferation. 17-HSD5 can also carry out multiple catalyses in hormone-dependent cancer cells. In addition to 17-HSDs 1 and 5 some other family members possess such dual-activity as well, and their inhibition decreases hor- mone-dependent cancer proliferation. The multi-specificity of 17-HSD1 is structurally based on the pseudo-symmetric androgens that can accommodate the narrow enzyme substrate tunnel by both normal and alternative binding.
    [Show full text]
  • The Regulation of Hydroxysteroid 17Β-Dehydrogenase Type 1 and 2
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 37), pp: 62183-62194 Research Paper The regulation of hydroxysteroid 17β-dehydrogenase type 1 and 2 gene expression in breast cancer cell lines by estradiol, dihydrotestosterone, microRNAs, and genes related to breast cancer Erik Hilborn1, Olle Stål1, Andrey Alexeyenko2,3 and Agneta Jansson1 1Department of Clinical and Experimental Medicine and Department of Oncology, Faculty of Health Sciences, Linköping University, Linköping, Sweden 2Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden 3National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Solna, Sweden Correspondence to: Erik Hilborn, email: [email protected] Keywords: breast cancer, HSD17B1, HSD17B2, miRNA Received: September 23, 2016 Accepted: June 01, 2017 Published: July 10, 2017 Copyright: Hilborn et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Aim: To investigate the influence of estrogen, androgen, microRNAs, and genes implicated in breast cancer on the expression of HSD17B1 and HSD17B2. Materials: Breast cancer cell lines ZR-75-1, MCF7, T47D, SK-BR-3, and the immortalized epithelial cell line MCF10A were used. Cells were treated either with estradiol or dihydrotestosterone for 6, 24, 48 hours, or 7 days or treated with miRNAs or siRNAs predicted to influence HSD17B expression. Results and discussion: Estradiol treatment decreased HSD17B1 expression and had a time-dependent effect on HSD17B2 expression. This effect was lost in estrogen receptor-α down-regulated or negative cell lines.
    [Show full text]
  • The Resilience of a Potent Androgen in Prostate Cancer Patients After Castration
    11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration Gido Snaterse, … , Martijn P. Lolkema, Johannes Hofland JCI Insight. 2021. https://doi.org/10.1172/jci.insight.148507. Clinical Medicine In-Press Preview Endocrinology Oncology Graphical abstract Find the latest version: https://jci.me/148507/pdf 1 1 11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after 2 castration 3 Gido Snaterse MSc1,a, Lisanne F. van Dessel MD2,a, Job van Riet BSc2, Angela E. Taylor PhD3, 4 Michelle van der Vlugt-Daane BSc2, Paul Hamberg MD4, Prof Ronald de Wit MD PhD, Jenny A. 1 3 2 5 Visser PhD , Prof Wiebke Arlt MD DSc. , Martijn P. Lolkema MD PhD , Johannes Hofland MD 6 PhD1# 7 1. Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Rotterdam, The 8 Netherlands 9 2. Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus MC, Rotterdam, 10 The Netherlands 11 3. Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, 12 United Kingdom 13 4. Department of Internal Medicine, Franciscus Gasthuis & Vlietland, Rotterdam, the 14 Netherlands 15 a These authors contributed equally 16 # Corresponding author 17 18 Address for correspondence: Johannes Hofland, Department of Internal Medicine, Erasmus MC, 19 Rg5, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. 20 Tel.: +31 10 704 0446. 21 E-mail: [email protected] 22 Keywords: Androgens, CRPC, LC-MS/MS, Prostate cancer, Testosterone 23 Financial Disclosure: 24 Dr Hamberg reported being on an advisory board of Astellas. 25 Dr de Wit reported receiving speaker fees from Merck and Sanofi, advisory fees from Sanofi, 26 Merck, Janssen, Astellas, Roche and Bayer, and institutional research grants from Sanofi and 2 27 Bayer.
    [Show full text]
  • Clinical, Genetic, and Structural Basis of Apparent Mineralocorticoid
    Clinical, genetic, and structural basis of apparent PNAS PLUS mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency Mabel Yaua,1, Shozeb Haiderb,1, Ahmed Khattaba, Chen Lingb, Mehr Mathewc, Samir Zaidid, Madison Blochc, Monica Patelc, Sinead Ewertb, Wafa Abdullahe, Aysenur Toygarc, Vitalii Mudryib, Maryam Al Badie, Mouch Alzubdib, Robert C. Wilsonf, Hanan Said Al Azkawie, Hatice Nur Ozdemirc, Wahid Abu-Amerc, Jozef Hertecantg, Maryam Razzaghy-Azarh, John W. Funderi, Aisha Al Senanie, Li Sunc, Se-Min Kimc, Tony Yuenc,2, Mone Zaidic,2,3, and Maria I. Newa,2,3 aDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029; bDepartment of Pharmaceutical and Biological Chemistry, University College London School of Pharmacy, London WC1N 1AX, United Kingdom; cDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029; dDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114; eDepartment of Pediatrics, Royal Hospital, Muscat 111, Oman; fDepartment of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, SC 29425; gDepartment of Pediatrics, Tawam Hospital, Abu Dhabi 15258, United Arab Emirates; hMetabolic Disorders Research Center, Tehran University of Medical Sciences, Tehran 1417613151, Iran; and iDepartment of Medicine, Monash University, Clayton, VIC 3800, Australia Contributed by Maria I. New, November 14, 2017 (sent for review September 21, 2017; reviewed by Vidya Chandran Darbari, Lucia Ghizzoni, and Carlos Isales) Mutations in 11β-hydroxysteroid dehydrogenase type 2 gene fective metabolism of cortisol to cortisone leads to the pathogno- (HSD11B2) cause an extraordinarily rare autosomal recessive dis- monic elevation in the ratio of urinary tetrahydrocortisol (THF) plus order, apparent mineralocorticoid excess (AME).
    [Show full text]
  • Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG And
    cancers Article Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer Oluwaseun Adebayo Bamodu 1,2,3,* , Kai-Yi Tzou 1,4, Chia-Da Lin 1,4, Su-Wei Hu 1,4, Yuan-Hung Wang 2,5, Wen-Ling Wu 1,4, Kuan-Chou Chen 1,4,5,6 and Chia-Chang Wu 1,4,5,6,* 1 Department of Urology, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan; [email protected] (K.-Y.T.); [email protected] (C.-D.L.); [email protected] (S.-W.H.); [email protected] (W.-L.W.); [email protected] (K.-C.C.) 2 Department of Medical Research and Education, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan; [email protected] 3 Department of Hematology and Oncology, Cancer Center, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan 4 TMU Research Center of Urology and Kidney, Taipei Medical University, Taipei City 11031, Taiwan 5 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan 6 Department of Urology, School of Medicine, College of Medicine, Taipei Medical University, Citation: Bamodu, O.A.; Tzou, K.-Y.; Taipei City 11031, Taiwan Lin, C.-D.; Hu, S.-W.; Wang, Y.-H.; * Correspondence: [email protected] (O.A.B.); [email protected] (C.-C.W.); Wu, W.-L.; Chen, K.-C.; Wu, C.-C. Tel.: +886-02-22490088 (ext.
    [Show full text]